The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Open accessAbstract
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. RESULTS: A total of 13,970 patients underwent randomization; 6992 were assigned to the bempedoic acid group and 6978 to the placebo group. The median duration of follow-up was 40.6 months. The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21.1 percentage points in favor of bempedoic acid. The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = 0.001). Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels. CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The CLEAR Outcomes trial randomized 13,970 patients with established or high risk for CVD, intolerance to statins, and LDL-C level ≥ 100 mg/dL to receive bempedoic acid (180 mg daily) or placebo [131]. Bempedoic acid reduced the risk of MACE by − 13% (HR 0.87, 95% CI 0.79–0.96, p = 0.004) and resulted in a − 21.1% greater reduction in LDL-C levels”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is important to note that ∼19% of individuals were on very-low-dose statin therapy at baseline (135).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This substantially exceeded other oral non-statin therapies, as ezetimibe lowers LDL-C by 18–25%, bempedoic acid by 17–21%, and their combination by ∼36–40% [[21], [22], [23], [24]]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CLEAR-Outcomes trial, an intriguing observation was that BA’s relative risk reduction for the primary composite outcome differed significantly between the primary and secondary prevention groups (with hazard ratios of 0.68 versus 0.91 respectively) [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A higher frequency of gout (3.1% versus 2.1%) and cholelithiasis (2.2% versus 1.2%) was observed with bempedoic acid than with placebo [133].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
The cited source says what the claim attributes to it.
In the citing paper
“The Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid or Placebo (CLEAR Outcomes) trial found a reduction in four-point major adverse cardiovascular events by 13% compared with placebo for individuals with established ASCVD (70% of population) or at high risk for ASCVD (30% of population) a”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) trial reported cardiovascular outcomes in a mixed population of primary and secondary prevention patients unable or unwilling to take guideline-recommended doses of statins.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This primary prevention cohort was a prespecified subgroup that represented 30% of the total enrolled within a larger trial that included a mixed population of primary and secondary prevention patients.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This was followed by recent data from the CLEAR Outcomes trial showing reductions in clinical events [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These differences are likely attributable to a lack of statistical power and imprecise estimates as the largest outcomes-based trial, CLEAR Outcomes, had not yet been published at the time of the previous meta-analyses but is included in our meta-analysis [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, most of the trials included in this analysis had relatively short follow-up durations with the exception of CLEAR Outcomes [7] and CLEAR Harmony [12].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Among the 6992 patients assigned to the active arm of the study 45% had T2DM.Bempedoic acid was associated with a significantly lower incidence of the four-component composite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or coronary revascularization and a higher incidence of some adverse events (gout and cholelithiasis) at the 40.6 month follow-up.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationStatins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Goldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Ferrières, J., Ray, K. K., Catapano, A. L., Allouche, R., Becker, C., Bardet, A., & Farnier, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1748457 · Cited by 1
Self-citationRay, K. K., Aguiar, C., Arca, M., Connolly, D. L., Eriksson, M., Ferrières, J., Laufs, U., Mostaza, J., Nanchen, D., Boachie, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101577 · Cited by 1
Self-citationBempedoic acid and increased serum uric acid levels: a matter of concern?
Bonanni, L., Biolo, M., Marodin, G., Portinari, C., Simioni, P., & Ferri, N. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104755 · Cited by 1
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
Federici, M., Buzzetti, R., Candido, R., Cosmo, S. D., Pirillo, A., Russo, G., Sesti, G., & Avogaro, A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03185-1 · Cited by 1
Almahmeed, W. A., Sabbour, H. M., Shantouf, R. S., Aljaberi, A. K., Tamimi, H. E., Lootah, F. B., Sayed, N. A., Ali, J. A., Akbar, M. A. J., Shehab, A., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100569 · Cited by 1
Ciaula, A. D., Khalil, M., Garruti, G., & Portincasa, P. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101056 · Cited by 2
Fancher, A. J., López‐Candales, A., & Sawalha, K. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.216 · Cited by 1
Xie, S., Galimberti, F., Olmastroni, E., Catapano, A. L., & Casula, M. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104851 · Cited by 1
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0191 · Cited by 1
Roubille, F., Kharlamov, A., Lenz, M. W., Madonna, R., Delmas, C., Schaubroeck, H., Morosin, M., Wojta, J., Vandenbriele, C., Kernéis, M., et al. (2026) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuag086 · Cited by 1
Comparison of the 2025 ESC/EAS and 2026 ACC/AHA guidelines for dyslipidaemia management
Finocchiaro, S., Mauro, M. S., Bordonaro, C., Bujak, K., Cosentino, C., Cutore, L., Leo, G. D., Nasisi, F., Redigolo, P., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag413 · Cited by 1
Palabıyık, E. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01033-8 · Cited by 1
Bonaca, M. P., Canonico, M. E., Li, N., Sasiela, W. J., Nissen, S. E., Lincoff, A. M., & Nicholls, S. J. (2026) · Circulation · doi:10.1161/circulationaha.125.078469 · Cited by 2
Self-citationCardiovascular risk management in the elderly: a dilemma in daily clinical practice
Dacquino, G. M., Galati, G., Genovese, L., Bravo, F. F., Bernardi, M., Spadafora, L., & Pedretti, R. F. E. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag316 · Cited by 1
Dyslipidaemia in elderly and stroke patients
Kahali, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.013 · Cited by 1
Treatment of dyslipidemia in acute coronary syndrome
Yadav, S., & Sawhney, J. P. S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.011 · Cited by 1
Bempedoic Acid in Secondary Prevention
Mousavi, I., Nambi, V., Abushamat, L. A., Al-Kindi, S. G., Shapiro, M. D., Sperling, L. S., Virani, S. S., & Minhas, A. M. K. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100715 · Cited by 1
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.004 · Cited by 1
Gebauer, K., Malyar, N. M., Varghese, J., Reinecke, H., Brix, T. J., & Engelbertz, C. M. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02542-5 · Cited by 1
Chen, K., Du, Y., & Zhu, Y. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00840-9 · Cited by 1
Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
Huang, S.-J., Huang, P. H., Song, N.-N., Jia, X.-H., Gao, H., Lu, Z., & Wen, X. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105003 · Cited by 1
Nguyen, D. Q., Hwang, J., Rohatgi, A. K., Joshi, P. H., Khera, A., Peterson, E. D., & Návar, A. M. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101421 · Cited by 1
Musculoskeletal Adverse Events Associated With Bempedoic Acid: A Real-World Pharmacovigilance Study
He, Y., Wei, Y., Jiang, X., & Lu, J. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001792 · Cited by 1
ATP-citrate lyase: carcinogenesis and therapeutic advances
Meng, L., Wang, Y., Cai, Q., Xi, Y., Sun, D., Zhao, M., & Chen, Q. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026028 · Cited by 1
Zhu, B., Ma, Y., Shao, Q., Cui, J., & Zhenyan, F. (2026) · Medicine · doi:10.1097/md.0000000000047898 · Cited by 1
ATP-citrate lyase is a critical regulator of physiological and pathological angiogenesis
Xu, C., Lin, Y., Wang, Z., Feng, C., Luo, L., Guo, S., Zhang, H., Liu, L., Fan, A., Qi, P., et al. (2026) · Angiogenesis · doi:10.1007/s10456-026-10037-9 · Cited by 1
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 1
Lipid-lowering therapies: the arrows in the quiver and future bullets
D’ARRIGO, P., Filosco, F., & Cinnirella, G. (2026) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.07002-4 · Cited by 1
Emerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target
Wei, M., Tao, M., Tan, H., Jin, Z., Yang, Y., Xiao, Z., Li, G., & Chen, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2652826 · Cited by 1
Zingano, C. P., Brennan, D. M., Bloedon, L. T., Li, N., Herout, P. M., Powell, H. A., Spiazzi, B. F., Ray, K. K., Nicholls, S. J., Nissen, S. E., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag195 · Cited by 1
Self-citationPathophysiology and pharmacotherapy of cardiovascular complications in metabolic syndrome
Dhalla, N. S., Patel, C. A., Beladiya, J., Mehta, A. A., & Gandhi, T. R. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.04.007 · Cited by 1
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Gouda, P., Secemsky, E. A., Hess, C. N., Arya, S., Fokorede, F., Mehran, R., Bonaca, M. P., Patel, M. R., & Jones, W. S. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107446 · Cited by 1
Management of dyslipidaemia in patients with comorbidities—facing the challenge: heart failure
Drexel, H., Frick, M., Zirlik, A., Niessner, A., Huber, K., Tamargo, J., Dobrev, D., MADER, A., & Agewall, S. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag033 · Cited by 1
Hsieh, I.-C., Chen, D., Chu, C., Chang, Y., Tzeng, B., Huang, T., Lin, H., Chuang, W., Huang, C., Yeh, J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049917 · Cited by 1
[Lipids - Diagnostics and treatment in diabetes mellitus (Update 2026)].
Wascher, T. C., Paulweber, B., Toplak, H., Saely, C. H., Drexel, H., Föger, B., Hoppichler, F., Stulnig, T., Stingl, H., Höllerl, F., et al. (2026) · PubMed · doi:10.1007/s00508-025-02652-1 · Cited by 1
Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk
Antwi, K., Luvai, A., Downie, P., Ghani, A., Maple, M., & Mbagaya, W. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54141 · Cited by 1
Liu, H., Zhang, Y., & Li, M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.237 · Cited by 1
Puri, R., Mehta, V., Sahoo, P. K., & Yusuf, J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.010 · Cited by 1
Lipidtherapie bei Patienten mit Diabetes mellitus – Praxisempfehlung der DDG, DGE und DGK
Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Marx-Schütt, K., Zirlik, A., & Müller‐Wieland, D. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2891-4582 · Cited by 1
Hyperlipidemia management: A calibrated approach
Firnhaber, J. M. (2023) · The Journal of Family Practice · doi:10.12788/jfp.0576 · Cited by 1
Lipid modification in people with diabetes
Morris, D. (2023) · Prescriber · doi:10.1002/psb.2053 · Cited by 1
Albackr, H. B., Waili, K. A., Almahmeed, W. A., Jarallah, M. A., Amin, M., Al‐Rasadi, K., Batais, M. A., Almigbal, T. H., Youssef, A. A., AlGhamdi, M. A., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230710145604 · Cited by 1
Kardiovaskuläre Therapie bei chronischer Nierenerkrankung
Brandenburg, V. M., Saritas, T., Schirmer, S. H., Rogacev, K. S., & Heine, G. H. (2023) · Herz · doi:10.1007/s00059-023-05205-2 · Cited by 1
Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
Мазеркина, И. А., Букатина, Т. М., & Aleksandrova, T. V. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-292-302 · Cited by 1
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0248 · Cited by 1
Dyslipoproteinaemia: Important Concern in Type 2 Diabetes
Kumwenda, M. J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002514 · Cited by 1
Conquering cholesterol: a report from the front lines
Libby, P., Pinkosky, S. L., & Nissen, S. E. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad152 · Cited by 1
Self-citationLipid lowering therapy: implications of recent clinical trials
Backes, J. M., & Hilleman, D. E. (2024) · Future Cardiology · doi:10.2217/fca-2023-0132 · Cited by 2
“Manganese bullet” targeting for dyslipidemia and plaque reversal
Luo, F., Wang, Y., Wang, X., & Chen, X. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1146 · Cited by 1
Effect of statin add-on therapy on cardiovascular mortality
Nelson, J. R., Le, V. T., Anderson, J. L., & Ciffone, N. A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1308695 · Cited by 1
Bempedoic Acid Reduces Major Adverse Cardiovascular Events for Statin-Intolerant Patients
Cunningham, J. M., & Kiazand, M. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08704-y · Cited by 1
The effect of lypolitics on atherosclerotic plaques of the artery
Darmenov, O., Issayeva, N., Zhaksybay, Z., Sadyrbayeva, G., & Bayanbay, N. A. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/202410001011 · Cited by 1
Raposeiras‐Roubín, S., Abu-Assi, E., Pérez-Rivera, J.-Á., Pérez, P. J., López, A. A., Tejedor, A. V., Pascual, M. J. C., Carrasquer, A., Jiménez-Méndez, C., González-Cambeiro, C., et al. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.05.004 · Cited by 1
Pharmacotherapies for Cardiovascular Disease Prevention
Ballard‐Hernandez, J., & Irwin, C. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_14 · Cited by 1
A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteins
Kelpsch, D. J., Zhang, L., Thierer, J. H., Cruz, A. G. R., Koren, K., Kumar, U., Lin, Y., Hensley, M. R., Sohn, M., Liu, J. O., et al. (2026) · eLife · doi:10.7554/elife.105314.3 · Cited by 1
Lipidtherapie bei Patienten mit Diabetes mellitus
Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Marx-Schütt, K., Zirlik, A., & Müller‐Wieland, D. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0484 · Cited by 1
Top 10 Tips for Using Statins in Clinical Practice
Rangwani, S. M., Maning, J., & Stone, N. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.025 · Cited by 1
Sciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
González-Guerrero, A., Climent, E., Benaiges, D., & Pedro‐Botet, J. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.500752 · Cited by 1
Stoll, F., Amato, S., Sauter, M., Burhenne, J., Weiß, J., Haefeli, W. E., & Blank, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010060 · Cited by 1
Bempedoic acid after statin-induced rhabdomyolysis
Irene, V., & Alex, H. (2024) · Acta Clinica Belgica · doi:10.1080/17843286.2025.2480697 · Cited by 1
Li, L., Sun, H., Jin, Z., Li, J., Fang, Y., Zuo, L., Sun, P., Li, Y., Richards, M., Foo, R., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.021 · Cited by 1
Schirmer, B., & Schuler, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_11 · Cited by 1
Schuitema, P. C. E., Stam‐Slob, M. C., Visseren, F. L. J., Koopal, C., the UCC-SMART Study Group, Cramer, M. J., van der Meer, M. G., van der Harst, P., Nathoe, H. M., van Setten, J., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf091 · Cited by 1
Šoóšová, I. (2024) · Cardiology letters · doi:10.4149/cardiol_2024_4_5 · Cited by 1
Severe hypertriglyceridemia after use of bempedoic acid
Bovy, V., & Bogaert, A.-M. (2023) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2023_003838 · Cited by 1
Kudaiberdieva, G. (2023) · Heart Vessels and Transplantation · doi:10.24969/hvt.2023.392 · Cited by 1
Lipidsenkende Therapie bei chronischer Nierenerkrankung im Erwachsenenalter
Klingel, R. (2023) · Nephrologie aktuell · doi:10.1055/a-2026-5196 · Cited by 1
Bempedoic acid benefits statin-intolerant patients at high cardiovascular risk
Tent, M. (2023) · doi:10.55788/88e583af · Cited by 1
Lipidmanagement zur Reduktion des kardiovaskulären Risikos bei Typ-2-Diabetes
Brandts, J. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01094-5 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_58 · Cited by 1
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0680 · Cited by 1
Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes
Lopez-Ayala, P., Glarner, N., & Mueller, C. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2305917 · Cited by 1
Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal
Ben‐Yehuda, O. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.06.003 · Cited by 1
Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk
Jialal, I., & Gounden, V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164915 · Cited by 2
A Metabolic Health Framework to Interpret Weight Gain Studies in People With HIV
Guaraldi, G., & Milić, J. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae646 · Cited by 1
The Expanding Oral Options for LDL Cholesterol Management
Brunham, L. R., Shapiro, M. D., & Nambi, V. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.175 · Cited by 2
Mechanism of fatty acid uptake and inhibition in human FATP2Preprint
Zhang, Z., Zhou, M., Huang, Y., Wu, W., Jiao, H., Dai, M., Liang, T., Wen, J., Cheng, Z., Ma, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.06.736331 · Cited by 1
Skrabic, R., Kumric, M., Santic, R., Skrabic, I., Pavlovic, N., Rusic, D., & Bozic, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1875074
PharmacotherapyFirst: A Multimedia Learning Resource
Munyer, T. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst
McGiness, T. P., Holbert, H., Hentrich, L., & Waite, L. H. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.lipid_overview
The latest news from American College of Cardiology 2023
Gragnano, F., & Calabrò, P. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad020
Omari, M., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113665
Five Recent Trials That Are Changing Cardiology Practice Across the World
Madivada, S. S. M., & Patnaik, A. N. (2023) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636231178191
Relação Metabólica e Inflamatória entre Covid-19 e Não-HDL-C
Alves, R. J. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230304
Bempedoinsäure bei Niereninsuffizienz
Grützmacher, P. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00667-1
Statins for Chronic Liver Disease and the Need for Randomized Controlled Trials
Abraldeṣ, J. G., & Moctezuma‐Velázquez, C. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.07.005
Vila, À., Pons, E., García, P. T., Vidal, D., López, S., & Grau, A. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.06.002
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant
Doggrell, S. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242259
Novel therapies in clinical use for the management of hyperlipidaemia
Mettananda, C. D. (2023) · Asian Journal of Internal Medicine · doi:10.4038/ajim.v2i2.105
Masson, W. M. (2023) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v26i3.7072
Hypercholesterinämie – Wen, wann, wie behandeln?
Merkel, M. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1956-9851
Aktuelle Strategien zur kardiovaskulären Risikoreduktion bei CKD
Patyna, S., & Speer, T. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00686-y
Konservative Therapie und Sekundärprävention der pAVK
Mühlberg, K. S. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2017-7742
Schettler, V. J. J. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-4775
Bempedoic acid, when and how to use it?
Masson, W. M., Nogueira, P., & Giraldo, G. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000213
Metadata
- Authors
- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C.-F., Li, N., Bloedon, L., Robinson, P., Horner, M., Sasiela, W. J., McCluskey, J., Davey, D., Fajardo-Campos, P., Petrovic, P., Fedacko, J., Zmuda, W., Lukyanov, Y., & Nicholls, S. J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cleveland Clinic, Cleveland (S.E.N., A.M.L., D.B., D.M., L.C., V.M., J.M., D.D.); Imperial College London, London (K.K.R.); University of Amsterdam Academic Medical Center, Amsterdam (J.J.P.K.), and University Medical Center Utrecht, Utrecht (D.E.G.) — both in the Netherlands; Hartford Hospital, Hartford, CT (P.D.T.); Brigham and Women’s Hospital, Harvard Medical School, Boston (P.L., J.P.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.E.B.); University of Kansas Medical Center, Kansas City (P.M.M.); Esperion Therapeutics, Ann Arbor, MI (M.J.L., C.-F.C., N.L., L.B., P.R., M.H., W.J.S.); Centro de Investigación Cardiovascular y Metabólica, Tijuana, Mexico (P.F.-C.); General Hospital Sveti Luka, Smederevo, Serbia (P.P.); Center of Clinical and Preclinical Research Medipark, Pavol Jozef Šafárik University, Košice, Slovakia (J.F.); Medicome, Oświęcim, Poland (W.Z.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (Y.L.); and Victorian Heart I...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-04-13
- Volume
- 388
- Issue
- 15
- Pages
- 1353-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323075797
- Semantic Scholar
- 33b876475ba15ddd5ffc66ad5046afe4cb9173b0
- Cited by
- 988
- References
- 21
- Citations by year
- 2026: 266 · 2025: 261 · 2024: 270 · 2023: 189
- FWCI
- 263.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Esperion Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, statin intolerance, ATP-citrate lyase inhibitor, LDL cholesterol lowering, major adverse cardiovascular events, cardiovascular disease prevention, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, hypercholesterolemia, lipid-lowering therapy, statin adverse effects
- MeSH terms
- Administration, Oral, Hypolipidemic Agents, Cardiovascular Diseases, Dicarboxylic Acids, Double-Blind Method, Fatty Acids, Humans, Myocardial Infarction, Myocardial Revascularization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
